Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

The latest update is out from Can-Fite BioPharma ( (CANF) ).

An informational consumer evaluation guide to best blood sugar supplement criteria for 2026, Akkermansia muciniphila and Bifidobacterium probiotic research, berberine botanical science, natural GLP-1 ...

Cafe Casino strengthens its presence in the No Deposit Casino Canada market by introducing structured online casino bonuses ...

Experiments conducted in genetically engineered mice reinforce that CSE protein (ordinarily known for producing hydrogen ...

Protein aggregation exhibits a dual role in biology, especially in neural systems. While pathogenic aggregates of proteins such as Aβ, tau, and α-synuclein ...